Needham analyst Michael Matson has maintained their bullish stance on AORT stock, giving a Buy rating today.
Michael Matson has given his Buy rating due to a combination of factors including Artivion’s potential for recovery and growth despite recent setbacks. Although the company’s fourth-quarter revenue for 2024 fell short of expectations, its EBITDA exceeded consensus, indicating strong operational efficiency. The cybersecurity issue that impacted sales is seen as a temporary hurdle, with expectations for a robust recovery in 2025. Additionally, Artivion’s key products such as On-X, stent grafts, and BioGlue showed positive growth in constant currency terms, which is a promising sign for future performance.
Geographically, the company experienced significant growth in Latin America, as well as steady growth in Asia Pacific and EMEA regions. While the cybersecurity issue is anticipated to affect the first quarter of 2024, the overall outlook for the remainder of 2025 is optimistic. The decision to slightly lower the price target reflects caution regarding the cybersecurity incident, but the overall growth prospects and operational strengths support the Buy rating.
In another report released today, JMP Securities also maintained a Buy rating on the stock with a $33.00 price target.
Based on the recent corporate insider activity of 77 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AORT in relation to earlier this year.
Questions or Comments about the article? Write to editor@tipranks.com